CollPlant Biotechnologies Ltd. (CLGN)

Market Cap	6.77M -81.7%
Revenue (ttm)	389,000 -84.3%
Net Income	-13.13M
EPS	-1.03
Shares Out	18.91M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	8,981,818
Open	0.2891
Previous Close	0.2897
Day's Range	0.2637 - 0.4127
52-Week Range	0.2637 - 3.1800
Beta	0.68
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 11, 2026

About CLGN

CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on its recombinant human collagen (rhCollagen) that is produced using its proprietary technology. The company offers regenerative dermal and soft tissue fillers; 3D-bioprinted regenerative breast implants; Collage, a combinant human Collagen type I solution; VergenixSTR, a soft tissue mat...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2004
• Employees: 39
• Stock Exchange: NASDAQ
• Ticker Symbol: CLGN
• Website: https://collplant.com

Financial Performance

In 2025, CollPlant Biotechnologies's revenue was $2.37 million, an increase of 360.39% compared to the previous year's $515,000. Losses were -$11.49 million, -30.83% less than in 2024.

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Aug 29, 2026

Data Sources Report a data error